Navigation Links
Paratek to Present Clinical Data in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
Date:10/14/2008

BOSTON, Oct. 14 /PRNewswire/ -- Paratek Pharmaceuticals, Inc. today announced the Company's lead product, amadacycline, formerly PTK 0796, a first-in-class aminomethylcycline, will be the subject of a Late Breaker poster presentation at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). ICAAC will be held in Washington, D.C. from October 25 - October 28, 2008.

More information on the poster session at ICAAC:

Sunday, October 26, 12:15 - 1:15 pm EST

Session 126; New Treatment Options in Skin and Soft Tissue Infections

Location: Hall C

Poster: L1515B

-- Safety and Efficacy of PTK 0796: Results of the Phase 2 Study in

Complicated Skin and Skin Structure Infections Following IV and

Oral Step-down Therapy.

About Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc. is engaged in the discovery and commercialization of new therapeutics that treat serious and life-threatening diseases, with a particular focus on the growing worldwide problem of antibiotic resistance. Paratek is advancing novel compounds that can circumvent or block bacterial resistance. Paratek's lead compound, amadacycline, formerly PTK 0796, is a broad-spectrum antibiotic derived from the tetracycline class with oral and IV formulations that is being developed for the treatment of the most common and serious hospital bacterial infections, including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus) and MDRSP (multi-drug resistant Streptococcus pneumoniae). Oral and IV formulations of amadacycline were compared to Zyvox (R) in a recently completed Phase 2 clinical study in complicated skin and skin structure infections (cSSSI). In addition to amadacycline, Paratek is also developing other broad- and narrow-spectrum tetracycline antibiotics to treat hospital and community infections based on its novel tetracycline chemistry expertise.

Outside of its tetracycline antibacterial program, Paratek has also identified small molecules that inhibit bacteria-specific transcription factors for Multiple Adaptational Response (MAR) genes which control bacterial virulence and resistance development.

Based upon a growing body of clinical research and as part of its effort to exploit its novel tetracycline derivatives and their unique mechanism of action in selected inflammatory and neurodegenerative conditions, Paratek has an active chemical synthesis effort to produce novel and diverse small molecules, with the goal of developing nonantibacterial compounds with improved activity in serious inflammatory and neurodegenerative diseases. In addition, Paratek is encouraged by early evidence of the ability of tetracycline derivatives to affect mRNA splicing, as in SMA, which may also have activity in related orphan genetic disorders, such as cystic fibrosis (CF) and Duchene Muscular Dystrophy.

Paratek has active collaborations with Merck & Co., MerckSerono, Warner-Chilcott and FSMA to develop tetracycline-derived small molecule drugs for broad-spectrum use in treating community-acquired bacterial infections, multiple sclerosis (MS), acne & rosacea, and spinal muscular atrophy (SMA), respectively. Paratek is privately held and headquartered in Boston, Massachusetts, USA. For more information about Paratek and its research and development initiatives, visit Paratek's website at http://www.paratekpharm.com.


'/>"/>
SOURCE Paratek Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Paratek Pharmaceuticals Announces the Close of $40 Million Private Placement to Finance Programs to Combat MRSA Infections
2. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
3. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
4. Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress
5. Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting
6. News Media Advisory: Worlds Leading Surgical Oncologists to Gather at McLaren Regional Medical Center to Present Latest Work on Breast, Gastrointestinal Cancer Treatments
7. National Study Presented at ACG 2008 Confirms New Device Functions Like Rear-View Mirror to Provide Improved View of the Colon
8. Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting
9. Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
10. In Vivo Data on Taligen Therapeutics Pipeline Candidates Presented at the XXII International Complement Workshop
11. Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... VIEW, Calif. , Feb. 10, 2016 ... of a synergistic confluence of various technologies ... value propositions, previously unavailable. These opportunities create ... and convergence, in turn, drives the development ... entrepreneurial scenario is characterized by technology convergences, ...
(Date:2/10/2016)... , Feb. 10, 2016 /PRNewswire/ - The President of ... announced the release of an anti-radiation product from ... revolutionary breakthrough in the treatment of cancer using ... It will assist in the healing of radiation ... will also protect only the healthy cells from ...
(Date:2/10/2016)... , Feb. 10, 2016 Intouch ... recently identified an industry-wide trend regarding the evolution ... allows organizations to efficiently deliver compelling sales presentations ... 2011 and another in 2015, Intouch uncovered that ... tablet devices and DSAs, many are not using ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... Early this week, Team Iconic at ... of Nestlé KITKAT as the first global confectionery brand sourced from 100% sustainable cocoa. ... the quality of their product, through activities that focus on better farming, better lives ...
(Date:2/10/2016)... ... February 10, 2016 , ... As part of its ongoing series of ... Each webinar features a dynamic expert and thoughtful presentation to give attendees a ... facilities. Both events are free to attend, but registration is required. ...
(Date:2/10/2016)... ... February 10, 2016 , ... Emergency rooms provide emergency care to ... this can leave patients with dental emergencies at risk of losing a tooth or ... dental care. , Common dental emergencies include:, , Avulsed ...
(Date:2/10/2016)... ... 10, 2016 , ... Intalere’s 2016 Executive Forum, taking place ... the country’s top healthcare executives to share insights on transformational strategies to drive ... is the provider-centric perspective, experience, expertise and strategy shared by the participants,” said ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... Emmy award winner and inspirational speaker Jan Fox will serve as keynote speaker ... Boldly will provide participants with tools to more effectively communicate with their own ...
Breaking Medicine News(10 mins):